Pierre Fabre Laboratories is exploring the potential of Artificial Intelligence to launch a new generation of clinical studies in dermo-cosmetics
medical research
March 12, 2026
From 100 to 600 patients: to support patients suffering from acne, Avène, Pierre Fabre Laboratories' leading brand, is strengthening the robustness of its clinical studies via data augmentation through Artificial Intelligence.
TOULOUSE, France, March 11, 2026 /PRNewswire/ -- Avène, the leading brand in French pharmacies*, in partnership with Toulouse-based HealthTech company BotDesign, has announced a major breakthrough in the field of clinical studies in dermo-cosmetics.
In 2026, Avène will conduct a comparative clinical study to evaluate the efficacy of its new treatment for acne-prone skin, Avène Cleanance Comedomed+, in the maintenance phase following oral isotretinoin treatment in adults suffering from severe to very severe acne.
Avène is renowned for its dermatological expertise, inspired by therapeutic know-how, and has been committed to improving the treatment of skin pathologies since 1990. It is thus becoming the first brand to use Artificial Intelligence in clinical studies for dermo-cosmetics.
A concrete illustration of Pierre Fabre Laboratories' "Supportive Care" strategy.
This study is unique in two ways: due to its scientific ambition and because it fully aligns with the "supportive care" strategy of Pierre Fabre Laboratories, launched in 2025.
"We belong to a group that has always been rooted in pharmaceuticals and dermo-cosmetics. Our medical expertise gives us a head start in understanding patients and their pathologies. We are ideally positioned to offer treatment protocols based on the pathology, combining dermo-cosmetics with medication. We are already preparing solutions to go further, by developing dermo-cosmetic innovations capable of extending and amplifying the action of the medication or delaying its necessity. Because these are dermo-cosmetics, they can be used over the long term, unlike many drug treatments," explains Dr. Gautier Doat, Eau Thermale Avène Medical Director.
To continue reading, https://www.pierre-fabre.com/en/news/avene-artificial-intelligence-clinical-studies-dermo-cosmetics
For more information, visit www.pierre-fabre.com, @Laboratoires Pierre Fabre, @Pierre Fabre Oncology
About Eau Thermale Avène: https://www.eau-thermale-avene.fr/
Press contact: Caroline Perdrix Thomas
caroline.perdrix@pierre-fabre.com
*Source: GERS – SOG Early – Pharmacy Channel – Dermo-cosmetics market definition established by Pierre Fabre laboratories – Origin: Sell Out – Cumulative data up to December 2025 in volume (units) and value (revenue inc. taxes).
SOURCE Pierre Fabre Laboratories
AAPR aggregates press releases and media statements from around the world to assist our news partners with identifying and creating timely and relevant news. All of the press releases published on this website are third-party content and AAP was not involved in the creation of it. Read the full terms.
